References
- Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et
al. Cancer incidence and mortality worldwide: sources, methods and
major patterns in GLOBOCAN 2012. Int J Cancer 2015;136(5):E359-86.
- Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ,
Petros JA, Andriole GL. Measurement of prostate-specific antigen in
serum as a screening test for prostate cancer. N Engl J Med
1991;324:1156–1161.
- Djavan B, Zlotta A, Kratzik C. et al. PSA, PSA density, PSA density of
transition zone, free/total PSA ratio and PSA velocity for early
detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL.
Urology, 54: 517-522, 1999.
- Yoshida K, Honda M, Sumi S, et al. Levels of free
prostate-specificantigen (PSA) can be selectively measured by heat
treatment of serum: free/ total-PSA ratios improve detection of
prostate carcinoma. Clin Chim Acta. 1999;280:195–203.
- Catalona WJ, Southwick PC, Slawin KM, et al. Comparison of percent
free PSA, PSA density, and age-specific PSA cutoffs for prostate
cancer detection and staging. Urology 56:255-260, 2000.
- Albertsen PC , Hanley JA , Fine J . 20-year outcomes following
conservative management of clinically localized prostate cancer .JAMA 2005 ; 293 : 2095 – 101.
- Lu-Yao GL , Albertsen PC , Moore DF et al . Outcomes of localized
prostate cancer following conservative management . JAMA 2009 ; 3 02 :
1202 – 9.
- Ceylan C, Gazel E, Keleş İ, Doluoǧlu Ö, Yıǧman M. Can the free/total
PSA ratio predict the Gleason score before prostate biopsy? Curr
Urol. 2016;9:24–7.
- Liu J, Wang ZQ, Li M, Zhou MY, Yu YF, Zhan WW. Establishment of two
new predictive models for prostate cancer to determine whether to
require prostate biopsy when the PSA level is in the diagnostic gray
zone (4-10 ng ml(-1)). Asian J Androl. 2020;22(2):213-6.
- Epstein JI, Egevad L, Amin MB, et al. The 2014 International Society
of Urological Pathology (ISUP) consensus conference on Gleason grading
of prostatic carcinoma: definition of grading patterns and proposal
for a new grading system. Am J Surg Pathol 2016;40:244– 52.
- Salami SS, Palapattu GS, Partin AW, Morgan TM. Campbell Walsh Wein
Urology, 12th Edition.Elsevier, 2020. Section XIV Prostate; 108.
Prostate cancer biomarkers.
- Ilic D, Djulbegovic M, Jung JH, et al. Prostate cancer screening with
prostate-specific antigen (PSA) test: a systematic review and
meta-analysis. BMJ 2018;362:k3519.
- Omri N, Kamil M, Alexander K, et al. Association between PSA density
and pathologically significant prostate cancer: The impact of prostate
volume. The Prostate. 2020;1‐6.
- Han C, Liu S, Qin XB, Ma S, Zhu LN, Wang XY. MRI combined with PSA
density in detecting clinically significant prostate cancer in
patients with PSA serum levels of 4∼10ng/mL: Biparametric versus
multiparametric MRI. Diagn Interv Imaging 2020;101:235-244.
- Wei C, Chen T, Zhang Y, et al.
Biparametric
prostate MRI and clinical indicators predict clinically significant
prostate cancer in men with “gray zone” PSA levels. European
Journal of Radiology 127 (2020) 108977
- Ha YS, Yu J, Salmasi AH, Patel N, Parihar J, Singer EA, et
al. Prostate-specific antigen density toward a better cutoff to
identify better candidates for active surveillance. Urology 2014;
84: 365–71.
- Corcoran NM, Casey RG, Hong MKH et al: The ability of
prostate-specific antigen (PSA) density to predict an upgrade in
Gleason score between initial prostate biopsy and prostatectomy
diminishes with increasing tumour grade due to reduced PSA secretion
per unit tumour volume. BJU Int 2012; 110: 36-42.